// App-Quantinova.ai

P1072 : SARS-CoV-2 drives JAK1/2-dependent local complement hyperactivation

Researchers

Presenter

  • Bingyu Yan

Principal Investigators

  • Daniel Chauss

  • Luopin Wang

  • Erin West

  • Carmen Mirabelli

  • Charles J. Zhang

  • Eva-Maria Nichols

  • Nazish Malik

  • Richard Gregory

  • Marcus Bantscheff

  • Sonja Ghidelli-Disse

  • Martin Kolev

  • Tristan Frum

  • Jason R. Spence

  • Jonathan Z. Sexton

  • Konstantinos D. Alysandratos

  • Darrell N. Kotton

  • Stefania Pittaluga

  • Jack Bibby

  • Nathalie Niyonzima

  • Matthew R. Olson

  • Shahram Kordasti

  • Didier Portilla

  • Christiane E. Wobus

  • Arian Laurence

  • Michail S. Lionakis

  • Claudia Kemper

  • Behdad Afzali

  • Majid Kazemian

Medical Centers

  • Purdue University

  • NIDDK

  • NIH

  • NHLBI

  • Univ. Hosp. Frankfurt

  • Goethe-University

  • univ. of michigan

  • Michigan Medicine at Univ. of Michigan

  • Michigan Medicine

  • Ctr. for Regenerative Medicine of Boston Univ. and Boston Medical Center

  • Boston Univ. Sch. of Med.

  • NCI

  • Norwegian Univ. of Sci. and Technology

  • King’s Col. London

  • Guy’s Hospital

  • Univ of Virginia

  • Univ of Oxford

  • NIAID

  • Univ. of Lubeck

Locations

  • United Kingdom

  • Turkey

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

Disease

  • Coronavirus disease

Biomarkers

  • Complement Component 3a

  • Janus kinase

Drug/Treatment

  • Ruxolitinib phosphate

  • Angiotensin II

  • Interferon

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved